Corcept Therapeutics Incorporated · NASDAQ:CORT

Mokari Atabak sold 80,000 Corcept Therapeutics Incorporated shares (Form 4)

Traded Jul 30, 2026 · Filed Aug 3, 2026

On Jul 30, 2026, Mokari Atabak (Chief Financial Officer) sold 80,000 Corcept Therapeutics Incorporated shares at an average US$114.72 for US$9.18M under a trading plan, leaving 16,130 shares. Filed Aug 3, 2026 (Form 4).

Sold
80,000 shares
Price
US$114.72 average (US$105.54 to US$120.67)
Value
US$9.18M
Holding after
16,130 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jul 30, 2026Common StockOption exercise80,000US$23.0696,130Direct
Jul 30, 2026Common StockSale4,200US$105.5491,930Direct
Jul 30, 2026Common StockSale8,956US$106.9682,974Direct
Jul 30, 2026Common StockSale400US$108.4682,574Direct
Jul 30, 2026Common StockSale2,202US$110.0380,372Direct
Jul 30, 2026Common StockSale600US$110.9579,772Direct
Jul 30, 2026Common StockSale4,700US$113.1875,072Direct
Jul 30, 2026Common StockSale15,477US$114.9659,595Direct
Jul 30, 2026Common StockSale14,222US$115.8745,373Direct
Jul 30, 2026Common StockSale7,089US$116.9638,284Direct
Jul 30, 2026Common StockSale8,267US$117.9330,017Direct
Jul 30, 2026Common StockSale4,783US$118.7325,234Direct
Jul 30, 2026Common StockSale8,103US$119.9517,131Direct
Jul 30, 2026Common StockSale1,001US$120.6716,130Direct

Source

View original at SEC

Related